Get the Stockscreener App
0.196
1.51%
-0.003
Coeptis Therapeutics Holdings Inc stock is traded at $0.196, with a volume of 130.32K.
It is down -1.51% in the last 24 hours and down -6.40% over the past month.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
See More
Previous Close:
$0.199
Open:
$0.21
24h Volume:
130.32K
Relative Volume:
0.52
Market Cap:
$7.93M
Revenue:
-
Net Income/Loss:
$-16.31M
P/E Ratio:
-0.2049
EPS:
-0.9564
Net Cash Flow:
$-7.46M
1W Performance:
-2.49%
1M Performance:
-6.40%
6M Performance:
-44.02%
1Y Performance:
-83.93%
1-Day Range:
$0.195
$0.21
1-Week Range:
$0.19
$0.21
52-Week Range:
$0.1511
$1.30
Coeptis Therapeutics Holdings Inc Stock (COEP) Company Profile
Name
Coeptis Therapeutics Holdings Inc
Sector
Industry
Phone
724-934-6467
Address
105 BRADFORD ROAD, SUITE 420, WEXFORD
Compare COEP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| COEP | 0.415 | 2.70M | 0 | 0 | 0 | 0.00 |
| GOODO | 22.16 | 372.90M | 0 | 0 | 0 | 0.00 |
| PSNYW | 0.141 | 297.56M | 2.07B | -1.42B | -1.37B | -0.1344 |
| MOBBW | 0.16 | 278.60M | 0 | 0 | 0 | 0.00 |
| SHMD | 2.61 | 114.98M | 0 | 0 | 0 | 0.00 |
| JUNE | 4.95 | 63.87M | 0 | 0 | 0 | 0.00 |
Coeptis Therapeutics Holdings Inc Stock (COEP) Latest News
Armistice Capital, LLC's Strategic Acquisition in Coeptis Therap - GuruFocus.com
Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development - Quantisnow
Coeptis broadens NK cell tech license for emergency use - Investing.com India
Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use - Citizentribune
Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy - Longview News-Journal
A Tale of Resilience: Coeptis Therapeutics Holdings Inc Amid Stock Market Turbulence - The InvestChronicle
Is Coeptis Therapeutics Holdings Inc (COEP) a good investment opportunity? - US Post News
Coeptis Therapeutics Holdings Inc (COEP)’s stock price range in the last year - US Post News
Coeptis Therapeutics appoints new auditor for fiscal year 2024 By Investing.com - Investing.com South Africa
Coeptis Therapeutics appoints new auditor for fiscal year 2024 - Investing.com
Market Insights: Coeptis Therapeutics Holdings Inc (COEP)’s Notable Gain of 5.00, Closing at 0.17 - The Dwinnex
CERo Therapeutics Hldgs (NASDAQ:CERO) Stock Quotes, Forecast and News Summary - Benzinga
COEP stock touches 52-week low at $0.17 amid market challenges - Investing.com Canada
Cepton (NASDAQ:CPTN) vs. China Zenix Auto International (OTCMKTS:ZXAIY) Head-To-Head Analysis - Defense World
Cogent Biosciences, Inc. (NASDAQ:COGT) Shares Purchased by Rhumbline Advisers - Defense World
Is Cooper Companies Stock Outperforming The Nasdaq? - Barchart
FDA Approval Propels ZVRA To 52-week High, ADMA, CPRX, TVTX Also Reach New Peaks - Nasdaq
Tucows CEO Elliot Noss sells shares worth over $125k - Investing.com India
Choreo LLC Purchases Shares of 23,033 Coty Inc. (NYSE:COTY) - Defense World
Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing - The Malaysian Reserve
Coherent Corp (COHR)’s Market Momentum: Closing Strong at 80.98, Up 3.93 - The Dwinnex
Coeptis Therapeutics secures Nasdaq listing extension - Investing.com India
Coeptis Therapeutics secures Nasdaq listing extension By Investing.com - Investing.com Australia
Exicure Shares More Than Double After Nasdaq Listing Extension - MarketWatch
Exicure Stock Is Soaring After The Bell: What's Driving The Action? - Benzinga
COHR’s Wild Ride: Up 82.75% – What’s Next for COHR? - The InvestChronicle
Cogent Biosciences (NASDAQ:COGT) Stock Price Up 4.1% - Defense World
Choreo LLC Takes $333,000 Position in The Cooper Companies, Inc. (NASDAQ:COO) - Defense World
Quest Partners LLC Acquires New Stake in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Exicure Inc (XCUR) rating downgrades by Chardan Capital Markets - Knox Daily
Cogent Biosciences Inc (COGT) stock analysis: A comprehensive overview - US Post News
Coeptis Therapeutics Announces Research Involving SNAP-CAR Accep - GuruFocus.com
Choreo LLC Buys Shares of 6,902 Ziff Davis, Inc. (NASDAQ:ZD) - Defense World
Coeptis Therapeutics (NASDAQ:COEP) Stock Price Down 4.1% - Defense World
Is Cogent Biosciences Inc (COGT) positioned for future growth? - SETE News
Quarterly Metrics: Quick and Current Ratios for Cogent Biosciences Inc (COGT) - The Dwinnex
Coherent Corp (COHR) receives a Buy rating from Needham - Knox Daily
Bank of New York Mellon Corp Buys 45,770 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Coeptis Therapeutics progresses in cell therapy trials - Investing.com
Coeptis Therapeutics progresses in cell therapy trials By Investing.com - Investing.com UK
Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to Shareholders - PR Newswire
Coeptis Therapeutics (NASDAQ:COEP) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS - Defense World
Coeptis Therapeutics to Present at the Emerging Growth Conferenc - GuruFocus.com
Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Sees Large Growth in Short Interest - Defense World
Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting - Longview News-Journal
Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting - Longview News-Journal
Coeptis Therapeutics retracts financial statements due to errors - Investing.com
Daily Progress: Coeptis Therapeutics Holdings Inc (COEP) Drop -0.88, Closing at 0.20 - The Dwinnex
Holdings of Coeptis Therapeutics Holdings Inc (COEP) are aligned with the stars - SETE News
Riding the Waves: A Guide to Investing in COEP Stock - The InvestChronicle
Was anything negative for Coeptis Therapeutics Holdings Inc (COEP) stock last session? - US Post News
Coeptis Therapeutics Holdings Inc Stock (COEP) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.66%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):